Description

Cagrilintide + Retatrutide Bundle — Omegatide Bundle

De Cagrilintide + Retatrutide bundle represents the forefront of metabolic peptide research. This kit combines a long-acting amylin analog with a groundbreaking triple incretin receptor agonist. As a result, the bundle offers researchers two complementary mechanisms for studying appetite regulation, energy homeostasis, and weight management.

Moreover, the focuses Cagrilintide Retatrutide bundle focus on broader metabolic parameters. For instance, recent phase 2 and phase 3 studies also include liver fat, cardiometabolic risk factors, and bone density as outcome measures. This makes the combination particularly interesting for researchers who wish to study multiple metabolic domains simultaneously.

What Is the Cagrilintide + Retatrutide Metabolic Stack?

This metabolic peptide research kit couples two compounds that surpass the market-leading GLP-1 monotherapies in efficacy. Cagrilintide acts primarily via amylin receptors in the brainstem and hypothalamus. Retatrutide simultaneously activates three different receptor types. Together, they therefore cover both the amylin and incretin axes.

That dual pathway mechanism is precisely what makes the bundle scientifically interesting. Because the two peptides act via different receptors, they complement each other rather than overlap. This allows researchers to study both signaling pathways simultaneously within a single protocol.

Cagrilintide: Background and Research Results

Cagrilintide is a long-acting amylin analogue from Novo Nordisk, currently in Phase 3 clinical trials. Amylin is a pancreatic hormone that is released together with insulin after a meal. It plays a key role in satiety and delaying gastric emptying.

Phase 2 research showed convincing results. For instance, participants receiving 4,5 mg of Cagrilintide per week achieved an average weight loss of 10,8% compared to 3,0% with placebo. Thus, Cagrilintide performed better than liraglutide 3,0 mg as the active comparator. Moreover, weight reduction occurred at all investigated doses (0,3–4,5 mg), which underscores the robustness of the effect.

Furthermore, combined administration with semaglutide — designated as CagriSema — showed even stronger results. In a phase 3a study (REDEFINE 2), the CagriSema group achieved an average weight loss of 13,7% versus 3,4% with placebo after 68 weeks. At the same time, HbA1c dropped to 6,5% or lower in 73,5% of the participants.

What Is Being Investigated at Cagrilintide?

• Central appetite suppression via amylin receptors in the hypothalamus and brainstem
• Delay of gastric emptying and reduction of postprandial glucose peaks
• Glucagon suppression and improvement of insulin sensitivity
• Synergistic weight reduction in combination with GLP-1 receptor agonists
• Lipid profile and triglyceride concentrations in obese subjects

Scientific References — Cagrilintide

• Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a phase 2 trial. Lancet. 2021. PubMed PMID 34798060
• Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (REDEFINE 2). N Engl J Med / PubMed. 2025. PubMed PMID 40544432
• Enebo LB, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg. Lancet. 2021; 397: 1736-1748. PubMed PMID 33894838
• Hathur B, et al. Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide as Anti-Obesity Medications: A Systematic Review and Meta-Analysis. Indian J Endocrinol Metab. 2024;28(5):436–444. PMC11642503

Retatrutide: Background and Research Results

Retatrutide (LY3437943) is a first-in-class triple agonist from Eli Lilly. It simultaneously activates the GIP, GLP-1, and glucagon receptors. This fundamentally distinguishes Retatrutide from available GLP-1 monotherapies. The half-life is approximately six days, which allows for once-weekly subcutaneous administration.

The phase 2 results are impressive. In a randomized placebo-controlled study published in the New England Journal of Medicine, participants receiving 12 mg Retatrutide achieved an average weight loss of 24,2% after 48 weeks. By comparison, this was 22,8% in the 8 mg group. A weight loss of at least 5% occurred in 100% of participants in the 8 mg and 12 mg groups.

Moreover, phase 3 research (TRIUMPH-4) showed even stronger results. Participants who received 12 mg Retatrutide lost an average of 28,7% of their body weight after 68 weeks. At the same time, pain and physical functioning also improved significantly in patients with knee osteoarthritis. This confirms Retatrutide's potential as a widely applicable research metabolic compound.

In addition, a phase 2a study in Nature Medicine investigated the effects on liver fat. In this study, retatrutide led to a reduction in liver fat of up to 82% in patients with metabolically associated steatotic liver disease (MASLD). This makes the compound relevant for a broad spectrum of metabolic research.

What Is Investigated in Retatrutide?

• Significant weight reduction via triple GIP/GLP-1/glucagon receptor activation
• Improvement of liver lipid content and MASLD parameters
• Cardiometabolic risk factors such as blood pressure, triglycerides, and non-HDL cholesterol
• Increased energy expenditure via glucagon receptor-mediated thermogenesis
• Glycemic control in type 2 diabetes with and without obesity
• Joint pain and physical functioning in obesity with knee osteoarthritis

Scientific References — Retatrutide

• Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6). NEJM DOI 10.1056/NEJMoa2301972
• Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30:2037–2048. Nature Medicine 2024
• Coskun T, et al. LY3437943, a Novel Triple Glucagon, GIP, and GLP-1 Receptor Agonist for Glycemic Control and Weight Loss. Cell Metab. 2022;34:1234–1247. PubMed PMID 35931020
• Efficacy and safety of retatrutide: a systematic review and meta-analysis. PMC. 2025. PMC12026077
• Retatrutide—A Game Changer in Obesity Pharmacotherapy. PMC. 2025. PMC12190491
• TRIUMPH-4 Phase 3 Results: Retatrutide Cuts Weight and Knee OA Pain. ClinicalTrials.gov NCT05931367. 2025. ClinicalTrials.gov NCT05931367

Why Combine Cagrilintide and Retatrutide?

The power of the Cagrilintide Retatrutide bundle The difference lies in mechanistic complementarity. Cagrilintide acts via amylin receptors in the central nervous system. Retatrutide, on the other hand, activates peripheral and central GIP, GLP-1, and glucagon receptors. Because they therefore act via completely different receptors, they hardly overlap and reinforce each other's effects.

In concrete terms, this means that Cagrilintide enhances satiety signals from the brain. At the same time, Retatrutide increases energy expenditure and promotes fat oxidation via glucagon receptor activation. This creates a dual approach to weight regulation: reduced intake and increased burning simultaneously.

Moreover, existing research shows that amylin analogues enhance the efficacy of GLP-1 agonists when administered together. Therefore, this bundle constitutes a logical and scientifically sound research model for studying combined anti-obesity mechanisms.

Applications in Research

Researchers are therefore increasingly opting for the Cagrilintide + Retatrutide bundle in the following research areas:

• Obesity pharmacology and multi-receptor agonism as a research model
• Interactions between amylin and incretin signaling pathways in weight regulation
• Hepatic steatosis and MASLD — liver fat reduction as an outcome measure
• Cardiometabolic risk factors such as blood pressure, lipids, and HbA1c
• Energy consumption, thermogenesis and fat oxidation via glucagon activation
• Combined pharmacology for long-term weight management

Who Is This Bundle Intended For?

De Cagrilintide Retatrutide bundle is ideally suited for the following research profiles:

• Pharmaceutical researchers studying next-generation anti-obesity mechanisms
• Endocrinologists researching incretin biology and amylin pharmacology
• Metabolic disease teams that model multireceptor agonism in vivo or in vitro
• Academic institutions with ongoing obesity or cardiometabolic research

Bundle Contents

• Cagrilintide — research-grade lyophilized peptide (≥98% purity, HPLC-verified)
• Retatrutide — research-grade lyophilized peptide (≥98% purity, HPLC-verified)

Both peptides are supplied as lyophilized powder. Mass spectrometry and HPLC certificates from accredited independent laboratories are available upon request.

Frequently Asked Questions about the Cagrilintide + Retatrutide Bundle

What is the difference between Cagrilintide and Retatrutide?

Cagrilintide is an amylin analog. It acts via amylin receptors in the brainstem and hypothalamus to promote satiety. Retatrutide is a triple agonist that simultaneously activates GIP, GLP-1, and glucagon receptors. In short: Cagrilintide reduces food intake, while Retatrutide also increases energy expenditure.

Is Cagrilintide the same as CagriSema?

No. CagriSema is the fixed combination of Cagrilintide and semaglutide from Novo Nordisk. In this bundle, you combine Cagrilintide with Retatrutide — a mechanistically different triple agonist from Eli Lilly. As a result, the bundle offers a unique research model outside the CagriSema framework.

Are Cagrilintide and Retatrutide approved for human use?

No, neither is currently. Cagrilintide is in Phase 3 clinical trials. Retatrutide is also in Phase 3, with multiple outcome expectations in 2026. Neither currently has approval from the FDA, EMA, or any other regulatory authority for therapeutic use. We are offering the bundle exclusively for scientific laboratory research.

Scientific References

1. Lau DCW, et al. Once-weekly cagrilintide for weight management: a phase 2 trial. Lancet. 2021. PubMed PMID 34798060
2. Cagrilintide-Semaglutide in Adults with Obesity and Type 2 Diabetes (REDEFINE 2). PubMed. 2025. PubMed PMID 40544432
3. Enebo LB, et al. Safety, tolerability, pharmacokinetics of cagrilintide with semaglutide. Lancet. 2021; 397: 1736-1748. PubMed PMID 33894838
4. Hathur B, et al. Efficacy and Safety of Cagrilintide: A Systematic Review and Meta-Analysis. Indian J Endocrinol Metab. 2024;28(5):436–444. PMC11642503
5. Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2. N Engl J Med. 2023;389(6). NEJM DOI 10.1056/NEJMoa2301972
6. Sanyal AJ, et al. Retatrutide for metabolic dysfunction-associated steatotic liver disease. Nat Med. 2024; 30: 2037-2048. Nature Medicine 2024
7. Coskun T, et al. LY3437943: Novel Triple GIP, GLP-1, and Glucagon Receptor Agonist. Cell Metab. 2022; 34: 1234-1247. PubMed PMID 35931020
8. Efficacy and safety of retatrutide: systematic review and meta-analysis. PMC. 2025. PMC12026077
9. Retatrutide—A Game Changer in Obesity Pharmacotherapy. PMC. 2025. PMC12190491
10. TRIUMPH-4 Phase 3: Retatrutide Cuts Weight and Knee OA Pain. ClinicalTrials.gov NCT05931367. 2025. ClinicalTrials.gov NCT05931367

⚠ For research purposes only — Disclaimer: This product is intended exclusively for in vitro and laboratory researchIt is not intended for use in humans or animals, self-administration, diagnosis, treatment or prevention of any disease or medical condition. Both Cagrilintide and Retatrutide are research compounds and possess not regarding approval from the FDA, EMA or any equivalent regulatory authority for therapeutic use. Researchers must comply with all applicable local laws and regulations. Keep out of reach of children. Handle in accordance with Good Laboratory Practice (GLP) guidelines.